SAN FRANCISCO--(BUSINESS WIRE)--VIA Pharmaceuticals, Inc. (NASDAQ: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it received notification from The NASDAQ Stock Market that it has been approved for listing on The NASDAQ Capital Market. In addition, VIA reported that it has received notification from the NASDAQ Listing Qualification Panel that the Company has demonstrated compliance with the Panel’s prior decisions and all applicable listing requirements, and accordingly, has granted VIA’s request for continued listing on The NASDAQ Capital Market. Following this determination, the Panel concluded its hearing proceedings.
